Seeking Alpha

John H. Ford's  Instablog

John H. Ford
Send Message
For the past 30 years, I have been involved in startups, as a founder, and active investor. My first company was purchased by Johnson & Johnson, which set the foundation for future investments. My level of trading escalated after graduating from college, primarily as a result of my... More
View John H. Ford's Instablogs on:
  • NASDAQ Up Listing And Institutional Buying Could Double Finjan's Shareprice

    Finjan is extremely undervalued right now, and there's an imminent catalyst that could instantly double the share price; the NASDAQ up listing. As many of my readers remember, Organovo (ONVO) went from $3.90 to $13.65 following the company's up listing.

    Best of all, the delay in Finjan's up listing has driven Finjan shares below $6 so I have been an aggressive buyer over the last few days. Once investors realize an up listing is probable, we could see share price appreciation before the up listing.

    But what investors don't realize is that the up listing is not nearly as important as what will happen after the up listing. Once Finjan has a NASDAQ listing, major institutions will be able to accumulate shares. With Finjan's low float, any level of institutional buying could push the shareprice significantly higher.

    The other factor that investors seem to have forgotten is that Finjan could announce a major settlement at any time, given the 5 litigations that are currently underway. Depending upon the magnitude of the settlements, it would not be surprising to see Finjan trading in the $15-$20 range.

    In my opinion Finjan is extremely undervalued at this price level, and with the probability of a NASDAQ up listing, institutional buying, and settlement announcements before the end of this year, the upside potential is large, and downside risk is limited.

    Disclaimer and disclosure: It is probable that the author and his associates have a position in the subject securities consistent with the opinion expressed in this article and they reserve the right to buy and/or sell the securities mentioned in this article, at any time without further notice. For complete disclosure and disclaimer information please click here.

    Disclosure: I am long FNJN.

    Apr 10 11:14 AM | Link | 2 Comments
  • Mission Statement

    To provide all investors with asymmetrical trades that generate 50% to 100% returns per trade.

    Jan 01 9:51 AM | Link | 1 Comment
  • Could ChromaDex's Niagen Reverse The Aging Process? Possibly

    ChromaDex shares have risen over 130% since my original Seeking Alpha article. Since then a new development has occurred that could be very positive for shareholders.

    In a study published Thursday in the journal Cell, researchers from Harvard Medical School identified a breakdown in cell communication in animals that causes aging to accelerate. This is important for ChromaDex because this study suggested that increasing NAD could reverse the aging process.

    When the researchers looked at the muscle from 2-year-old mice that had been given a compound that increased NAD, they found that in three indicators of aging (insulin resistance, inflammation and muscle wasting), the tissue in the mice looked like that of 6-month old mice.

    In humans, that would be like the muscle of a 60-year-old transforming into the muscle of a 20-year-old, according to the researchers.

    What's important for ChromaDex is that the company appears to have the only oral compound, Niagen, that is capable of boosting NAD. In the Harvard study, scientists used a compound that needed to be injected, which would not be practical commercially.

    Here is a link with more information on this Harvard study.

    Disclosure: I am long OTCQB:CDXC.

    Tags: CDXC
    Dec 24 12:01 PM | Link | Comment!
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.